Infliximab Therapy

  • Sèverine Vermeire
  • Gert Van Assche
  • Paul Rutgeerts


Inflammatory Bowel Disease Ulcerative Colitis Infusion Reaction Crohn Disease Mucosal Healing 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Burnham JM, Shults J, Semeao E, et al. Body-composition alterations consistent with cachexia in children and young adults with Crohn disease. Am J Clin Nutr 2005;82:413–20.PubMedGoogle Scholar
  2. 2.
    Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn disease. Gut 1994;35:360–2.PubMedCrossRefGoogle Scholar
  3. 3.
    Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn disease. Gut 1995;37:674–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease. Gastroenterology 2000;119:895–902.PubMedCrossRefGoogle Scholar
  6. 6.
    Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn disease. The North American Crohn Study Group Investigators. N Engl J Med 1995;332:292–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn disease. North American Crohn Study Group Investigators. N Engl J Med 2000;342:1627–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:760–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Ording Olsen K, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002;122:15–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Griffiths AM, Ohlsson A, Sherman PM, et al. Meta-analysis of enteral nutrition as a primary treatment of active Crohn disease. Gastroenterology 1995;108:1056–67.PubMedCrossRefGoogle Scholar
  11. 11.
    Lochs H, Dejong C, Hammarqvist F, et al. ESPEN Guidelines on Enteral Nutrition: Gastroenterology. Clin Nutr 2006;25:260–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn disease. Clin Exp Immunol 1993;94:174–181.PubMedCrossRefGoogle Scholar
  13. 13.
    Nicholls S, Stephens S, Braegger CP, et al. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol 1993;46:757–760.PubMedCrossRefGoogle Scholar
  14. 14.
    Breese E, Michie C, Nicholls S, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455–1466.PubMedGoogle Scholar
  15. 15.
    Cornillie F, Shealy D, D’Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn disease. Aliment Pharmacol Ther 2001;15:463–473.PubMedCrossRefGoogle Scholar
  16. 16.
    Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145–1157.PubMedCrossRefGoogle Scholar
  17. 17.
    ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn disease. Gut 2002;50:206–211.Google Scholar
  18. 18.
    Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn disease. Gastroenterology 2003;124:1774–1785.PubMedCrossRefGoogle Scholar
  19. 19.
    Shen C, Maerten P, Geboes K, et al. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005;115:250–259.PubMedCrossRefGoogle Scholar
  20. 20.
    Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn disease. Crohn Disease cA2 Study Group. N Engl J Med 1997;337:1029–1035.PubMedCrossRefGoogle Scholar
  22. 22.
    Rutgeerts P, D’Haens G, Targan S, et al. Safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn disease. Gastroenterology 1999;117:761–769.PubMedCrossRefGoogle Scholar
  23. 23.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn disease: the ACCENT I randomised trial. Lancet 2002;359:1541–1549.PubMedCrossRefGoogle Scholar
  24. 24.
    Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn disease. Gastrointest Endosc 2006;63:433–42.PubMedCrossRefGoogle Scholar
  25. 25.
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn disease. N Engl J Med 1999;340:1398–1405.PubMedCrossRefGoogle Scholar
  26. 26.
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn disease. N Engl J Med 2004;350:934–936.CrossRefGoogle Scholar
  27. 27.
    Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn disease. Am J Gastroenterol 2003;98:332–339.PubMedCrossRefGoogle Scholar
  28. 28.
    van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence of persistence of Crohn disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002;45:39–45; discussion 45–46.PubMedCrossRefGoogle Scholar
  29. 29.
    Bell SJ, Halligan S, Windsor AC, et al. Response of fistulating Crohn disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003;17:387–393.PubMedCrossRefGoogle Scholar
  30. 30.
    Kugathasan S. Prolonged duration of response to infliximab in early pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2001;33:S40–43.PubMedCrossRefGoogle Scholar
  31. 31.
    Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn disease. Am J Gastroenterol 2003;98:833–838.PubMedCrossRefGoogle Scholar
  32. 32.
    Lamireau T, Cezard JP, Dabadie A, et al. French-speaking group for pediatric gastroenterology nutrition. Efficacy and tolerance of infliximab in children and adolescents with Crohn disease. Inflamm Bowel Dis 2004;10:745–750.PubMedCrossRefGoogle Scholar
  33. 33.
    de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in the Netherlands. J Pediatr Gastroenterol Nutr 2004;39:46–52.PubMedCrossRefGoogle Scholar
  34. 34.
    Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn disease. Dig Liver Dis 2004;36:342–347.PubMedCrossRefGoogle Scholar
  35. 35.
    Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr 2003;36:632–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Wewer V, Riis L, Vind I. Infliximab dependency in a national cohort of children with Crohn disease. J Pediatr Gastroenterol Nutr 2006;42:40–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Hyams J, Crandall W, Kugathasan S. Induction and maintenance infliximab therapy for the treatment. Gastroenterol 2007;132:863–73.CrossRefGoogle Scholar
  38. 38.
    Griffiths A, Hyams J, Crandall W et al. Height of growth delayed children with active Crohn disease improves during treatment with infliixmab. Gastroenterol 2006 Suppl; 130:A12.Google Scholar
  39. 39.
    Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol. 2003;98:104–11.PubMedCrossRefGoogle Scholar
  40. 40.
    Markowitz J, Hyams J, Mack D, et al. (for the Pediatric IBD Collaborative Research Group). Corticosteroid therapy in the age of infliximab: Acute and 1-year outcomes in newly diagnosed children with crohn disease. Clin Gastroenterol Hepatol. 2006;.Google Scholar
  41. 41.
    Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn disease. Aliment Pharmacol Ther 2003;18:425–31.PubMedCrossRefGoogle Scholar
  42. 42.
    Butcher S, Chahel H, Lord JM. Ageing and the neutrophil: no appetite for killing? mmunology 2000;100:411–6.Google Scholar
  43. 43.
    Vermeire S, Louis E, Carbonez A, et al. Belgian Group of Infliximab Expanded Access Program in Crohn Disease. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn disease. Am J Gastroenterol 2002;97:2357–2363.PubMedCrossRefGoogle Scholar
  44. 44.
    Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn disease. Gastroenterology 2002;123:707–713.PubMedCrossRefGoogle Scholar
  45. 45.
    Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn disease. Aliment Pharmacol Ther 2003;17:1451–1457.PubMedCrossRefGoogle Scholar
  46. 46.
    Mortimore M, Gibson PR, Selby WS, et al. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern Med J 2001;31:146–150.Google Scholar
  47. 47.
    Hommes D, Baert F, Van Assche G, et al. A randomized controlled trial evaluating the ideal medical management for Crohn disease (CD): top-down versus step-up strategies. Gastroenterology 2005;128:A-577.Google Scholar
  48. 48.
    Romeo E, Viola F, De Angelis G, Vernuccio A, Pannone V, Bizzarri B, Borrelli O, Cucchiara S. Infliximab as a first choice therapy in children with newly diagnosed Crohn’s disease (CD) promotes long-term sustained remission and alters the course of the disease. Gastroenterol 2006 Suppl; 130:A11.Google Scholar
  49. 49.
    WJ Sandborn, JF Colombel, J Panes J, et al. Higher remission and maintenance of response rates with subcutaneous monthly certolizumab pegol in patients with recent-onset crohn disease: Data from PRECiSE 2.Google Scholar
  50. 50.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.PubMedCrossRefGoogle Scholar
  51. 51.
    Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805–11.PubMedCrossRefGoogle Scholar
  52. 52.
    Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005;11:213–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Mamula P, Markowitz JE, Brown KA, et al. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2002;34:307–11.PubMedCrossRefGoogle Scholar
  54. 54.
    Mamula P, Markowitz JE, Cohen LJ, et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004;38:298–301.PubMedCrossRefGoogle Scholar
  55. 55.
    Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in pediatric patients with Crohn disease. Gastroenterology 2006;130:1069–77.PubMedCrossRefGoogle Scholar
  56. 56.
    Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn disease. N Engl J Med 2003;348:601–608.PubMedCrossRefGoogle Scholar
  57. 57.
    Friesen CA, Calabro C, Christenson K, et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004;39:265–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Seiderer J, Goke B, Ochsenkuhn T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Digestion 2004;70:3–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19–31.PubMedCrossRefGoogle Scholar
  60. 60.
    Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004;38:502–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315–24.PubMedCrossRefGoogle Scholar
  62. 62.
    Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003;17:75–84.PubMedCrossRefGoogle Scholar
  63. 63.
    Noman M, Vermeire S, Van Assche G, et al. The effectiveness of immunosuppression to suppress the formation of antibodies to infliximab in Crohn disease. Gastroenterology 2004;126:A-54–55.Google Scholar
  64. 64.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn disease: a randomized controlled trial. Gastroenterology 2003;124:917–924.PubMedCrossRefGoogle Scholar
  65. 65.
    Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn disease. Gastroenterology 2004;126:402–413.PubMedCrossRefGoogle Scholar
  66. 66.
    Deslandres C, Faure C, Dirks M, et al. Open label experience with adalimumab in pediatric Crohn disease patients who lost response or were intolerant to infliximab. Gastroenterol Suppl 2006;AW1199.Google Scholar
  67. 67.
    Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn disease: a prospective cohort study. Gastroenterology 2003;125:32–39.PubMedCrossRefGoogle Scholar
  68. 68.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098–1104.PubMedCrossRefGoogle Scholar
  69. 69.
    Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275–85.Google Scholar
  70. 70.
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621–30.PubMedCrossRefGoogle Scholar
  71. 71.
    Morley-Fletcher A, Borrelli O, Viola F, Barbato M, Gaeta A, et al. Outcome of viral infections in children with Inflammatory Bowel Disease (IBD) treated with infliximab and immunosuppressive drugs. PG2–20.Google Scholar
  72. 72.
    Toruner M, Loftus EV, Colombel JF, et al. Risk factors for opportunistic infections in inflammatory bowel diseases: a case-control study. Gastroenterol Suppl 2006;A-71.Google Scholar
  73. 73.
    Van Assche G, Paintaud G, D’Haens G, Baert F, Vermeire S, Noman M, Watier H, Magdelaine C, Rutgeerts P. Continuation of immunomodulators is not required to maintain adequate infliximab efficacy in patients with Crohn disease but may improve pharmacokinetics. Gastroenterol Suppl 2006;130:A-142.Google Scholar
  74. 74.
    Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024–30.PubMedCrossRefGoogle Scholar
  75. 75.
    Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, Baldassano RN. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005;40(2):220–2.PubMedCrossRefGoogle Scholar
  76. 76.
    Mittal MS, Milner BJ, Johnston PW, Culligan DJ. A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol 2006;76:531–4.PubMedCrossRefGoogle Scholar
  77. 77.
    Navarro JT Ribera JM, Mate JL, et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn disease treated with azathioprine. Leuk Lymphoma. 2003;44:531–3.PubMedCrossRefGoogle Scholar
  78. 78.
    Lemann M, et al. Gastroenterolog Suppl 1998;114:A1020.Google Scholar
  79. 79.
    Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849–53.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Sèverine Vermeire
    • Gert Van Assche
    • Paul Rutgeerts

    There are no affiliations available

    Personalised recommendations